IODOSORB◊ POWDER

Cadexomer powder with iodine

Description

IODOSORB◊ Powder is a sterile dark brown powder consisting of cadexomer (modified starch microbeads) with iodine. The cadexomer beads are biodegradable.
IODOSORB Powder will absorb excess exudate and slough from the wound bed, and kill bacteria at the wound surface.
In doing this, it transforms into a soft moist gel.

Indications

IODOSORB Powder is indicated for the topical treatment of chronic exuding wounds such as venous leg ulcers, diabetic foot ulcers and pressure injuries.
IODOSORB Powder can be used under compression therapy. IODOSORB Powder may be used on infected wounds. Where the product is used on infected wounds the infection should be inspected and treated as per local clinical protocol.

Contraindications

IODOSORB Powder should not be used on dry necrotic tissue, or on patients with a known sensitivity to iodine or any of the other components.
Do not use IODOSORB Powder on children, pregnant or lactating women, or patients with thyroid disorders (e.g. Hashimoto's thyroiditis or non-toxic nodular goitre).

Warnings

There is a potential risk of interaction with lithium, resulting in an increased possibility of hypothyroidism.
Do not use IODOSORB Powder concomitantly with mercurial antiseptics or taurolidine. If the patient is about to undergo thyroid function tests, they should inform the healthcare professional.

Precautions for use

The maximum dose of the product must be observed. Particular care must be taken when using in patients with renal impairment or patients who may develop thyroid complications due to iodine, especially when treating large wounds or during prolonged use.

- IODOSORB Powder is single patient use only and should not be re-used as

cross-contamination or infection may occur and the powder may be ineffective.

- The contents of the sachet should be used on one patient only.
- Do not use IODOSORB Powder in the vicinity of the eyes, ears, nose or mouth.
- The product is for external use only.
- IODOSORB Powder may cause a slight transient pain in the first hour after treatment. This is a sign that the product is beginning to clean the wound. Occasionally, IODOSORB Powder may cause the skin around the wound edges to swell or redden. This will usually pass. If these symptoms persist or if the patient experiences any other symptoms, they should contact the healthcare professional.
- Contact with the skin around the wound edges/intact skin should be minimised.
- It is possible for an adherent crust to form if the IODOSORB Powder is allowed to dry out.
- A single application of IODOSORB Powder should not exceed 50g (equivalent to 16 x 3g sachets) and not more than 150g (equivalent to 50 x 3g sachets) applied in one week.
- The duration of treatment should not exceed 3 months.

The product is for healthcare professional use only.

Instructions for use

Applying IODOSORB Powder

1. Wash hands thoroughly before and after use. Using gloved hands, clean the wound and the surrounding area with either a gentle stream of water or saline. DO NOT DRY the wound surface.
2. Apply IODOSORB Powder to the wound surface to form a layer 3mm deep, which conforms to the shape of the wound. Cover the wound completely with an appropriate secondary dressing. Apply compression bandaging if appropriate. Any remaining IODOSORB Powder should be discarded due to loss of sterility.

Changing IODOSORB Powder

1. IODOSORB Powder should be changed when it has become saturated with exudate and all the iodine has been released. This is indicated by loss of colour, usually two to three times a week. If the wound is discharging heavily, daily changes may be needed. If IODOSORB Powder does not

become saturated by exudate, the maximum time between changes is 3 days.

2. If necessary, soak the dressing for a few minutes, then remove.
3. Gently remove the IODOSORB Powder using a stream of water or saline.
4. Gently blot any excess fluid, leaving the wound surface slightly moist, before reapplying IODOSORB Powder.
5. Dispose of according to local clinical protocols, or throw away hygienically after use.

If during the use of this device you believe that a serious incident has occurred, please report it to the manufacturer and your competent authority.

Complaints@Smith-Nephew.com

A copy of the summary of safety and clinical performance (SSCP) is available via https://ec.europa.eu/tools/eudamed

Product Availability

66001286 7x3g

Date of issue 01/2025. Revision 01

This product may be covered by one or more US Patents. www.smith-nephew.com/patents

Do not use if package is damaged / Ne pas utiliser si l'emballage est endommagé / Bei beschädigter Verpackung nicht verwenden / No utilizar si el envase está dañado / Não utilizar se a embalagem estiver danificada / Non utilizzare se la confezione è danneggiata / Niet gebruiken als de verpakking beschadigd is / Må ikke anvendes, hvis emballagen er beskadiget / Må ikke brukes hvis pakningen er skadet / Ei saa käyttää, jos pakkaus on vaurioitunut / Använd inte om förpackningen är skadad / Nie używać, jeżeli opakowanie jest uszkodzone / Nepoužívajte, ak je balenie poškodené

Green Dot / Point vert / Grüner Punk / Punto Verde / Ponto Verde / Punto verde / Groene punt / Det grønne punkt / Grønt punkt / Vihreä piste / Den gröna punkten / Zielony punkt / Zelený bod

IODOSORB POWDER

CONTACTS

Manufacturer contacts, packaging notes and symbols (part 2 of 3)

IODOSORB POWDER

CONTACTS

Manufacturer contacts, packaging notes and symbols (part 3 of 3)

Smith & Nephew Medical Limited,
101 Hessle Road, Hull HU3 2BN England

◊Trade Mark of Smith+Nephew

© Smith+Nephew 2025

Printed in: Sweden / Imprimé en : Suède

Date of issue: 01/2025. Revision 01

www.smith-nephew.com

This product may be covered by one or more US Patents. www.smith-nephew.com/patents

Smith & Nephew Operations B.V.
Bloemlaan 2, 2132 NP Hoofddorp, Netherlands

46274 01502O5